.
MergerLinks Header Logo

New Deal


Announced

Kerry to acquire part of the Lactase Enzymes Business of Novozymes and Chr. Hansen for €150m.

Financials

Edit Data
Transaction Value£128m
Consideration TypeCash
Capital Owned-
Capital Bid For-
EV/Sales-
EV/EBITDA-
Share Price Premium-
One Off Charge-

Tags

Edit

Cross Border

Majority

Private

Denmark

Biotechnology

biotechnology solutions

enzyme technology

Single Bidder

biotechnology solution

Acquisition

Pending

Friendly

Synopsis

Edit

Kerry, a taste and nutrition partner for the food, beverage and pharmaceutical markets, agreed to acquire part of the Lactase Enzymes Business of Novozymes and Chr. Hansen for €150m. The Lactase Enzymes Business which includes NOLA® Products, further enhances Kerry's biotechnology solutions capability following the acquisitions of c-LEcta and Enmex. This acquisition adds enzyme technology which helps create lactose-free and sugar reduced dairy products, while preserving their authentic clean taste.

Search a database of more than 250,000 verified dealmakers

Receive automated updates on global transactions

Follow the activity, relationships and transactions of top dealmakers

No credit card required

© COPYRIGHT 2024 MERGERLINKS LIMITED.

ALL RIGHTS RESERVED.

15 BONHILL STREET, LONDON, EC2A 4DN, UNITED KINGDOM.

CONTACT US